| Combination of | |
|---|---|
| Testosterone propionate | Androgen; Anabolic steroid |
| Testosterone enanthate | Androgen; Anabolic steroid |
| Testosterone undecylenate | Androgen; Anabolic steroid |
| Clinical data | |
| Trade names | Durasteron |
| Other names | TP/TE/TUe |
| Routes of administration | Intramuscular injection |
Testosterone propionate/testosterone enanthate/testosterone undecylenate (TP/TE/TUe), sold under the brand name Durasteron, is an injectable combination medication of testosterone propionate (TP), testosterone valerate (TV), and testosterone undecylenate (TUe), all of which are androgens/anabolic steroids. It contains 20 mg TP, 80 mg TE, and 150 mg TUe (for a total of 250 mg testosterone ester and 169.5 mg free testosterone) in oil solution and is administered by intramuscular injection at regular intervals, for instance once every 3 or 4 weeks. Use of Durasteron by bodybuilders has been reported.
| Medication | Form | Major brand names | Duration |
|---|---|---|---|
| Testosterone | Aqueous suspension | Andronaq, Sterotate, Virosterone | 2–3 days |
| Testosterone propionate | Oil solution | Androteston, Perandren, Testoviron | 3–4 days |
| Testosterone phenylpropionate | Oil solution | Testolent | 8 days |
| Testosterone isobutyrate | Aqueous suspension | Agovirin Depot, Perandren M | 14 days |
| Mixed testosterone esters | Oil solution | Triolandren | 10–20 days |
| Mixed testosterone esters | Oil solution | Testosid Depot | 14–20 days |
| Testosterone enanthate | Oil solution | Delatestryl | 14–28 days |
| Testosterone cypionate | Oil solution | Depovirin | 14–28 days |
| Mixed testosterone esters | Oil solution | Sustanon 250 | 28 days |
| Testosterone undecanoate | Oil solution | Aveed, Nebido | 100 days |
| Testosterone buciclate | Aqueous suspension | 20 Aet-1, CDB-1781 | 90–120 days |
| Nandrolone phenylpropionate | Oil solution | Durabolin | 10 days |
| Nandrolone decanoate | Oil solution | Deca Durabolin | 21–28 days |
| Methandriol | Aqueous suspension | Notandron, Protandren | 8 days |
| Methandriol bisenanthoyl acetate | Oil solution | Notandron Depot | 16 days |
| Metenolone acetate | Oil solution | Primobolan | 3 days |
| Metenolone enanthate | Oil solution | Primobolan Depot | 14 days |
| Note: All are via i.m. injection. Footnotes: = TP, TV, and TUe. = TP and TKL. = TP, TPP, TiCa, and TD. = Studied but never marketed. = Developmental code names. Sources: See template. | |||
See also
- Testosterone propionate/testosterone valerate/testosterone undecylenate
- List of combined sex-hormonal preparations § Androgens
References
- ^ Daher EF, Silva Júnior GB, Queiroz AL, Ramos LM, Santos SQ, Barreto DM, et al. (2009). "Acute kidney injury due to anabolic steroid and vitamin supplement abuse: report of two cases and a literature review". International Urology and Nephrology. 41 (3): 717–23. doi:10.1007/s11255-009-9571-8. PMID 19387860. S2CID 23319246.
- ^ Davani-Davari D, Karimzadeh I, Khalili H (May 2019). "The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review". BMC Nephrology. 20 (1): 198. doi:10.1186/s12882-019-1384-0. PMC 6545019. PMID 31151420.
- Joël CA (1960). "Zur Behandlung männlicher Fertilitätsstörungen mit hohen Androgendosen" [For the treatment of male fertility disorders with high androgen doses]. Gynecologic and Obstetric Investigation. 150 (3): 149–156. doi:10.1159/000305737. ISSN 1423-002X.
20 mg Testosteronpropionat, 80 mg Testosteronheptanoat, 150 mg Testosteronundecylat (Durasteron Teva)
- Arends G, Zörnig H, Hager H, Frerichs G, Kern W (14 December 2013). Hagers Handbuch der pharmazeutischen Praxis: Für Apotheker, Arzneimittelhersteller, Drogisten, Ärzte u. Medizinalbeamte. Springer-Verlag. pp. 1145–. ISBN 978-3-662-36329-4.
At the same time, treatment with a long-acting testosterone preparation (Durasteron®) was instituted, with one injection given every four weeks.
- Spitz IM, Hirsch HJ, Landau H, Zylber-Haran E, Gross V, Rachmilewitz EA (October 1984). "TSH secretion in thalassemia". Journal of Endocrinological Investigation. 7 (5): 495–9. doi:10.1007/BF03348456. PMID 6439771. S2CID 20319052.
The male patients were given a long acting tes- tosterone preparation (Durasteron, Teva) 250 mg by im injection every 3 weeks for a total of 8 injections.
| Androgen receptor modulators | |||||||
|---|---|---|---|---|---|---|---|
| ARTooltip Androgen receptor |
| ||||||
| GPRC6A |
| ||||||
 | This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it. |